ARS Pharmaceuticals Inc Dossier - Source-backed chat

ARS Pharmaceuticals Inc

SPRYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.02

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $4.31Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $428.6M

Enterprise Value $517.1M

Shares Outstanding 99.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ARS Pharmaceuticals is successfully transitioning into a commercial-stage biopharmaceutical leader, driven by the rapid adoption of neffy, the first and only FDA-approved needle-free epinephrine nasal spray. With Q1 2026 revenues tripling year-over-year to $22.7 million and a strong cash position of $201 million, the company is well-capitalized to reach cash-flow break-even by mid-2027. The appointment of commercial veteran Donn Casale as President starting June 1, 2026, further strengthens execution capabilities. Key upcoming catalysts, including CVS Caremark formulary inclusion in July 2026 and Phase 2b chronic spontaneous urticaria (CSU) data in Q4 2026, present significant upside potential.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$23.25

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$25.0015%

Payer negotiations face unexpected friction, leading to higher-than-anticipated gross-to-net discounts or prolonged prior authorization requirements. High SG&A commercialization expenses persist, accelerating cash burn and forcing a dilutive capital raise before reaching break-even. Phase 2b CSU data fails to show competitive efficacy, limiting the platform's long-term growth valuation.

Base CaseCentral scenario

$28.6060%

Steady commercial execution of neffy in the U.S. drives consistent patient and prescriber growth, with gross-to-net retention stabilizing around the 50% target. CVS Caremark formulary inclusion is achieved in Q3 2026, and cash runway successfully funds operations through cash-flow break-even in mid-2027. Phase 2b CSU data is positive, supporting a Phase 3 trial in 2027.

Bull CaseUpside scenario

$32.0025%

Rapid commercial adoption of neffy accelerates, supported by unrestricted formulary access across all major payors (including CVS Caremark) and strong back-to-school seasonal demand in H2 2026. International rollouts in Europe, China, Japan, Australia, and Canada exceed expectations. Positive Phase 2b CSU data in Q4 2026 validates a multi-billion dollar pipeline expansion, driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage as the only approved needle-free epinephrine treatment (neffy) in major global markets.
Strong balance sheet with $201 million in cash and short-term investments, projected to fund operations to cash-flow break-even by mid-2027.
Proven commercial leadership bolstered by the appointment of Donn Casale as President, who previously scaled HEPLISAV-B to over $300 million in annualized revenue.
Significant pipeline optionality with the Phase 2b trial in chronic spontaneous urticaria (CSU) representing a multi-billion dollar peak sales opportunity.

Key Investment Risks

High commercialization and SG&A expenses ($72.2 million in Q1 2026) relative to current revenue levels.
Payer coverage and reimbursement risks, with gross-to-net retention targets highly dependent on successful formulary negotiations.
Potential competitive threats from emerging non-injection epinephrine alternatives currently in clinical development.

Thesis Invalidation Triggers

Failure to secure CVS Caremark commercial formulary inclusion by Q3 2026.
Negative or inconclusive interim data from the Phase 2b chronic spontaneous urticaria (CSU) trial in Q4 2026.
Significant deviation from the mid-2027 cash-flow break-even timeline, requiring dilutive equity financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.